Project Details
Description
HM2017-33 : Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
| Status | Finished |
|---|---|
| Effective start/end date | 11/1/17 → 4/30/23 |
Funding
- BRISTOL-MYERS SQUIBB COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.